

Please amend claims 32-34 and 41-46 as follows.

32. (Amended) An isolated cDNA comprising [a] the nucleotide sequence as provided in SEQ ID NO. 83.

D2
sub
c 33. (Amended) An isolated protein encoded by [a] cDNA comprising [a] the nucleotide sequence as provided in SEQ ID NO. 83.

34. (Amended) An isolated cDNA[s] encoding [an] the amino acid sequence as provided in SEQ ID NO. 62.

41. (Amended) An isolated cDNA comprising [a] the nucleotide sequence as provided in SEQ ID NO. 86.

D2
sub
c 2 42. (Amended) An isolated protein encoded by a cDNA comprising [a] the nucleotide sequence as provided in SEQ ID NO. 86.

D3 43. (Amended) An isolated cDNA[s] encoding [an] the amino acid sequence as provided in SEQ ID NO. 65.

44. (Amended) An isolated cDNA comprising [a] the nucleotide sequence as provided in SEQ ID NO. 87.

45. (Amended) An isolated protein encoded by a cDNA having [a] the nucleotide sequence as provided in SEQ ID NO. 87.

46. (Amended) An isolated cDNA[s] encoding the amino acid sequence provided in SEQ ID NO. 66.

REMARKS

Upon entry of this amendment, claims 32-34 and 41-46 are pending in this application with claims 35-40 and 47-108 canceled herein without prejudice to their entry into a related application.

As the Examiner has acknowledged in the Office Action mailed June 14, 2000, Applicants will provide a substitute specification upon the identification of allowable subject matter. A new abstract in compliance with MPEP§608.01(b) and to satisfy the Examiners objection in paragraph 5 of the outstanding Office Action will be included in the substitute specification. In addition, applicants will